Latest News and Press Releases

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Alvotech mun birta uppgjör fyrir fyrsta árshelming og annan ársfjórðung 2022, eftir lokun markaða í Bandaríkjunum miðvikudaginn 31. ágúst 2022. Kynningarfundur fyrir markaðsaðila verður haldinn...

REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in IcelandListing on the Main Market can increase...

Eftir skráningu félagsins á hlutabréfamarkað í Bandaríkjunum og á Íslandi hyggst Alvotech undirbúa að færa skráningu á Íslandi yfir á Aðalmarkaðinn Skráning á Aðalmarkaðnum eykur sýnileika og breikkar...

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in Iceland Listing on the Main Market can increase...

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...

Prolia® og Xgeva® (denosumab) eru lyf við sjúkdómum í beinum og námu tekjur af sölu þeirra um 730 milljörðum króna á síðasta áriAVT03 (denosumab) er fjórða líftæknilyfjahliðstæða Alvotech sem tekin er...

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...

Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” ...